Tuesday, February 18, 2014 1:20:10 PM
The reason you don't see it is not because it isn't there, but apparently because you either 1) haven't done enough DD to see why it is there or 2) need it better explained in terms you can understand so you can see it.
Nanoviricides work by "Trapping virus" by presenting on their surface exact copies (of critical portions) of the receptors that viruses MUST use to infect cells. Viruses cannot enter a cell unless they use certain receptors and unless they can enter a cell, they cannot reproduce and infect.
Many viruses use the same receptors. THis is particularly true of influenza A viruses that ALL use the same two receptors: Neuraminidase (the "N" in HXNX) and Hemagglutinin (the "H" in HXNX). The viral proteins (keys) that attach to the receptors (locks) may change but the locks are always the same.
That's why no matter what version of influenza A virus it is, the exact same FluCide would work for it. The virus MUST attach to the receptor or it cannot infect. But if it attaches to the H or N receptors then it will attach to and be trapped by Flucide.
Bottom line: just because you can't see something (especially at first glance) does not mean it's not there. If others say they can it's a good idea to talk to them rather than discounting it out of hand.
Nanoviricides work by "Trapping virus" by presenting on their surface exact copies (of critical portions) of the receptors that viruses MUST use to infect cells. Viruses cannot enter a cell unless they use certain receptors and unless they can enter a cell, they cannot reproduce and infect.
Many viruses use the same receptors. THis is particularly true of influenza A viruses that ALL use the same two receptors: Neuraminidase (the "N" in HXNX) and Hemagglutinin (the "H" in HXNX). The viral proteins (keys) that attach to the receptors (locks) may change but the locks are always the same.
That's why no matter what version of influenza A virus it is, the exact same FluCide would work for it. The virus MUST attach to the receptor or it cannot infect. But if it attaches to the H or N receptors then it will attach to and be trapped by Flucide.
Bottom line: just because you can't see something (especially at first glance) does not mean it's not there. If others say they can it's a good idea to talk to them rather than discounting it out of hand.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
